Innovative therapies in ewing sarcoma

Advances in Anatomic Pathology

Volumn 21, Issue 1, 2014, Pages 44-62

  Amaral, Ana Teresa ^a   Ordóñez, José Luis ^a   Otero Motta, Ana Pastora ^a   García Domínguez, Daniel J ^a   Sevillano, María Victoria ^a   De Álava, Enrique ^a,b  

^a Centro de Investigacion del Cancer   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Animal model; Clinical trials; Ewing sarcoma; Therapy

Indexed keywords

CAVEOLIN 1; CD99 ANTIGEN; CYTARABINE; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITHRAMYCIN; MONOCLONAL ANTIBODY; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PEVONEDISTAT; SOMATOMEDIN C RECEPTOR; TRABECTEDIN; ZOLEDRONIC ACID;

ANTIANGIOGENIC ACTIVITY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RECURRENCE; CLINICAL FEATURE; CLINICAL RESEARCH; DRUG RESEARCH; EPIGENETICS; EWING SARCOMA; EXPERIMENTAL THERAPY; HEALTH CARE QUALITY; HUMAN; IMMUNOTHERAPY; NONHUMAN; PATHOLOGIST; PREVALENCE; PRIORITY JOURNAL; REVIEW; TUMOR MICROENVIRONMENT;

ANIMALS; BONE NEOPLASMS; DISEASE MODELS, ANIMAL; HUMANS; MOLECULAR TARGETED THERAPY; SARCOMA, EWING; THERAPIES, INVESTIGATIONAL;

EID: 84890533901     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0000000000000003     Document Type: Review

References (163)

1. Tirode F, Laud-Duval K, Prieur A, et al. Mesenchymal stem cell features of Ewing tumors. Cancer Cell. 2007;11: 421-429. (Pubitemid 46680428)
2. von Levetzow C, Jiang X, Gwye Y, et al. Modeling initiation of Ewing sarcoma in human neural crest cells. PLoS One. 2011;6:e19305.
3. Germano G, Frapolli R, Belgiovine C, et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell. 2013;23: 249-262.
4. Germano G, Frapolli R, Simone M, et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res. 2010;70: 2235-2244.
5. Grohar PJ, Griffin LB, Yeung C, et al. Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. Neoplasia. 2011;13: 145-153.
6. Manara MC, Perdichizzi S, Serra M, et al. The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71. Int J Oncol. 2005;27: 1605-1616.
7. Lau L, Supko JG, Blaney S, et al. A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study. Clin Cancer Res. 2005;11: 672-677. (Pubitemid 40116894)
8. Baruchel S, Pappo A, Krailo M, et al. A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group. Eur J Cancer. 2012;48: 579-585.
9. Guirouilh-Barbat J, Antony S, Pommier Y. Zalypsis (PM00104) is a potent inducer of gamma-H2AX foci and reveals the importance of the C ring of trabectedin for transcription-coupled repair inhibition. Mol Cancer Ther. 2009;8: 2007-2014.
10. Leal JF, Garcia-Hernandez V, Moneo V, et al. Molecular pharmacology and antitumor activity of Zalypsis in several human cancer cell lines. Biochem Pharmacol. 2009;78: 162-170.
11. Ocio EM, Maiso P, Chen X, et al. Zalypsis: a novel marinederived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. Blood. 2009;113: 3781-3791.
12. Colado E, Paino T, Maiso P, et al. Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response. Haematologica. 2011;96: 687-695.
13. Romano M, Frapolli R, Zangarini M, et al. Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis(R) (PM00104). Int J Cancer. 2013;133: 2024-2033.
14. Grohar PJ, Woldemichael GM, Griffin LB, et al. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. J Natl Cancer Inst. 2011;103: 962-978.
15. Erkizan HV, Kong Y, Merchant M, et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med. 2009;15: 750-756.
16. Erkizan HV, Scher LJ, Gamble SE, et al. Novel peptide binds EWS-FLI1 and reduces the oncogenic potential in Ewing tumors. Cell Cycle. 2011;10: 3397-3408.
17. Barber-Rotenberg JS, Selvanathan SP, Kong Y, et al. Single enantiomer of YK-4-279 demonstrates specificity in targeting the oncogene EWS-FLI1. Oncotarget. 2012;3: 172-182.
18. Stegmaier K, Wong JS, Ross KN, et al. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/ FLI modulator in Ewing sarcoma. PLoS Med. 2007;4:e122.
19. Houghton PJ, Morton CL, Kang M, et al. Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program. Pediatr Blood Cancer. 2010;55: 1224-1226.
20. DuBois SG, Krailo MD, Lessnick SL, et al. Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2009;52: 324-327.
21. Martins AS, Mackintosh C, Martin DH, et al. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res. 2006;12: 3532-3540.
22. Martins AS, Ordonez JL, Garcia-Sanchez A, et al. A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study. Cancer Res. 2008;68: 6260-6270.
23. Garofalo C, Manara MC, Nicoletti G, et al. Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene. 2011; 30: 2730-2740.
24. Garofalo C, Mancarella C, Grilli A, et al. Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing's sarcoma. Mol Endocrinol. 2012;26: 1603-1616.
25. Macaulay VM, Middleton MR, Protheroe AS, et al. Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors. Ann Oncol. 2013;24: 784-791.
26. Juergens H, Daw NC, Geoerger B, et al. Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol. 2011;29: 4534-4540.
27. Houghton PJ, Morton CL, Gorlick R, et al. Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2010;54: 921-926.
28. Huang HJ, Angelo LS, Rodon J, et al. R1507, an anti-insulinlike growth factor-1 receptor (IGF-1R) antibody, and EWS/ FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/ IGFR/Akt axis. PLoS One. 2011;6:e26060.
29. Pappo AS, Patel SR, Crowley J, et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol. 2011;29: 4541-4547.
30. Quek R, Wang Q, Morgan JA, et al. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res. 2011;17: 871-879.
31. Martins AS, Ordonez JL, Amaral AT, et al. IGF1R signaling in Ewing sarcoma is shaped by clathrin-/caveolin-dependent endocytosis. PLoS One. 2011;6:e19846.
32. Tirado OM, Mateo-Lozano S, Villar J, et al. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells. Cancer Res. 2006;66: 9937-9947. (Pubitemid 44672046)
33. Sainz-Jaspeado M, Lagares-Tena L, Lasheras J, et al. Caveolin-1 modulates the ability of Ewing's sarcoma to metastasize. Mol Cancer Res. 2010;8: 1489-1500.
34. Tirado OM, MacCarthy CM, Fatima N, et al. Caveolin-1 promotes resistance to chemotherapy-induced apoptosis in Ewing's sarcoma cells by modulating PKCalpha phosphorylation. Int J Cancer. 2010;126: 426-436.
35. Scotlandi K, Baldini N, Cerisano V, et al. CD99 engagement: an effective therapeutic strategy for Ewing tumors. Cancer Res. 2000;60: 5134-5142.
36. Brenner JC, Feng FY, Han S, et al. PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer Res. 2012;72: 1608-1613.
37. Garnett MJ, Edelman EJ, Heidorn SJ, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012;483: 570-575.
38. Odri GA, Dumoucel S, Picarda G, et al. Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients. Cancer Res. 2010;70: 7610-7619.
39. Zhou Z, Guan H, Duan X, et al. Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma. Cancer. 2005;104: 1713-1720. (Pubitemid 41437436)
40. Mackintosh C, Garcia-Dominguez DJ, Ordonez JL, et al. WEE1 accumulation and deregulation of S-phase proteins mediate MLN4924 potent inhibitory effect on Ewing sarcoma cells. Oncogene. 2013;32: 1441-1451.
41. Patel N, Black J, Chen X, et al. DNA methylation and gene expression profiling of ewing sarcoma primary tumors reveal genes that are potential targets of epigenetic inactivation. Sarcoma. 2012;2012:498472.
42. Bennani-Baiti IM, Machado I, Llombart-Bosch A, et al. Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/ BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma. Hum Pathol. 2012;43: 1300-1307.
43. Fortson WS, Kayarthodi S, Fujimura Y, et al. Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells. Int J Oncol. 2011;39: 111-119.
44. Owen LA, Kowalewski AA, Lessnick SL. EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma. PLoS One. 2008;3:e1965.
45. Maris JM, Courtright J, Houghton PJ, et al. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008;50: 581-587. (Pubitemid 351155829)
46. George S, Merriam P, Maki RG, et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol. 2009;27: 3154-3160.
47. Gurney JG, Davis S, Severson RK, et al. Trends in cancer incidence among children in the US. Cancer. 1996;78: 532-541.
48. Lawlor ER, Mathers JA, Bainbridge T, et al. Peripheral primitive neuroectodermal tumors in adults: documentation by molecular analysis. J Clin Oncol. 1998;16: 1150-1157. (Pubitemid 28108752)
49. Zucman-Rossi J, Batzer MA, Stoneking M, et al. Interethnic polymorphism of EWS intron 6: genome plasticity mediated by Alu retroposition and recombination. Hum Genet. 1997; 99: 357-363. (Pubitemid 27095798)
50. Linabery AM, Ross JA. Childhood and adolescent cancer survival in the US by race and ethnicity for the diagnostic period 1975-1999. Cancer. 2008;113: 2575-2596.
51. Ladenstein R, Potschger U, Le Deley MC, et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro- EWING 99 trial. J Clin Oncol. 2011;28: 3284-3291.
52. Ludwig JA. Ewing sarcoma: historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future. Curr Opin Oncol. 2008;20: 412-418.
53. Parham DM, Hijazi Y, Steinberg SM, et al. Neuroectodermal differentiation in Ewing's sarcoma family of tumors does not predict tumor behavior. Hum Pathol. 1999;30: 911-918. (Pubitemid 29380514)
54. Mackintosh C, Ordonez JL, Garcia-Dominguez DJ, et al. 1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma. Oncogene. 2012;31: 1287-1298.
55. de Alava E, Antonescu CR, Panizo A, et al. Prognostic impact of P53 status in Ewing sarcoma. Cancer. 2000;89: 783-792. (Pubitemid 30658577)
56. Huang HY, Illei PB, Zhao Z, et al. Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol. 2005;23: 548-558. (Pubitemid 46224232)
57. Wei G, Antonescu CR, de Alava E, et al. Prognostic impact of INK4A deletion in Ewing sarcoma. Cancer. 2000;89: 793-799. (Pubitemid 30658578)
58. Hattinger CM, Potschger U, Tarkkanen M, et al. Prognostic impact of chromosomal aberrations in Ewing tumours. Br J Cancer. 2002;86: 1763-1769. (Pubitemid 34712921)
59. Ohali A, Avigad S, Cohen IJ, et al. Association between telomerase activity and outcome in patients with nonmetastatic Ewing family of tumors. J Clin Oncol. 2003;21: 3836-3843. (Pubitemid 46606239)
60. de Alava E, Kawai A, Healey JH, et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol. 1998;16: 1248-1255. (Pubitemid 28175736)
61. Le Deley MC, Delattre O, Schaefer KL, et al. Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J Clin Oncol. 2010;28: 1982-1988.
62. van Doorninck JA, Ji L, Schaub B, et al. Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2010;28: 1989-1994.
63. Hogendoorn PC, Athanasou N, Bielack S, et al. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(suppl 5): v204-v213.
64. Haeusler J, Ranft A, Boelling T, et al. The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES). Cancer. 2010;116: 443-450.
65. Turc-Carel C, Aurias A, Mugneret F, et al. Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12). Cancer Genet Cytogenet. 1988;32: 229-238.
66. Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature. 1992;359: 162-165.
67. Kovar H. Downstream EWS/FLI1 - upstream Ewing's sarcoma. Genome Med. 2010;2:8.
68. Kovar H. Context matters: the hen or egg problem in Ewing's sarcoma. Semin Cancer Biol. 2005;15: 189-196.
69. Herrero-Martin D, Osuna D, Ordonez JL, et al. Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target. Br J Cancer. 2009;101: 80-90.
70. Ordonez JL, Osuna D, Herrero D, et al. Advances in Ewing's sarcoma research: where are we now and what lies ahead? Cancer Res. 2009;69: 7140-7150.
71. Forni C, Minuzzo M, Virdis E, et al. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther. 2009;8: 449-457.
72. Grosso F, Jones RL, Demetri GD, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 2007; 8: 595-602. (Pubitemid 46995623)
73. Molinski TF, Dalisay DS, Lievens SL, et al. Drug development from marine natural products. Nat Rev Drug Discov. 2009;8: 69-85.
74. Duan Z, Choy E, Harmon D, et al. ZNF93 increases resistance to ET-743 (Trabectedin; Yondelis) and PM00104 (Zalypsis) in human cancer cell lines. PLoS One. 2009;4: e6967.
75. Duan Z, Choy E, Jimeno JM, et al. Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines. Cancer Chemother Pharmacol. 2009;63: 1121-1129.
76. Herrero AB, Martin-Castellanos C, Marco E, et al. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res. 2006;66: 8155-8162. (Pubitemid 44299183)
77. Soares DG, Escargueil AE, Poindessous V, et al. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc Natl Acad Sci USA. 2007;104: 13062-13067. (Pubitemid 351737593)
78. Tavecchio M, Simone M, Erba E, et al. Role of homologous recombination in trabectedin-induced DNA damage. Eur J Cancer. 2008;44: 609-618.
79. Toretsky JA, Erkizan V, Levenson A, et al. Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A. Cancer Res. 2006;66: 5574-5581. (Pubitemid 43927107)
80. Scotlandi K, Picci P. Targeting insulin-like growth factor 1 receptor in sarcomas. Curr Opin Oncol. 2008;20: 419-427.
81. Prieur A, Tirode F, Cohen P, et al. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol. 2004;24: 7275-7283. (Pubitemid 39014452)
82. Benini S, Manara MC, Cerisano V, et al. Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects. Int J Cancer. 2004;108: 358-366. (Pubitemid 37549600)
83. Benini S, Zuntini M, Manara MC, et al. Insulin-like growth factor binding protein 3as an anticancer molecule in Ewing's sarcoma. Int J Cancer. 2006;119: 1039-1046. (Pubitemid 44116910)
84. Silvany RE, Eliazer S, Wolff NC, et al. Interference with the constitutive activation of ERK1 and ERK2 impairs EWS/FLI-1- dependent transformation. Oncogene. 2000;19: 4523-4530.
85. Scotlandi K, Manara MC, Serra M, et al. Expression of insulin-like growth factor system components in Ewing's sarcoma and their association with survival. Eur J Cancer. 2011;47: 1258-1266.
86. Olmos D, Martins AS, Jones RL, et al. Targeting the insulinlike growth factor 1 receptor in Ewing's sarcoma: reality and expectations. Sarcoma. 2011;2011:402508.
87. Shin DH, Min HY, El-Naggar AK, et al. Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody. Mol Cancer Ther. 2011;10: 2437-2448.
88. Kolb EA, Gorlick R, Maris JM, et al. Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer. 2012;58: 729-735.
89. O'Neill A, Shah N, Zitomersky N, et al. Insulin-like growth factor 1 receptor as a therapeutic target in ewing sarcoma: lack of consistent upregulation or recurrent mutation and a review of the clinical trial literature. Sarcoma. 2013;2013: 450478.
90. Naing A, LoRusso P, Fu S, et al. Insulin growth factorreceptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res. 2012; 18: 2625-2631.
91. Hong DS, Banerji U, Tavana B, et al. Targeting the molecular chaperone heat shock protein 90 (HSP90): Lessons learned and future directions. Cancer Treat Rev. 2013;39: 375-387.
92. Jhaveri K, Taldone T, Modi S, et al. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta. 2012;1823: 742-755.
93. Di Fiore PP, De Camilli P. Endocytosis and signaling: an inseparable partnership. Cell. 2001;106: 1-4. (Pubitemid 32709950)
94. Wiechen K, Diatchenko L, Agoulnik A, et al. Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am J Pathol. 2001; 159: 1635-1643. (Pubitemid 33062506)
95. Wiechen K, Sers C, Agoulnik A, et al. Down-regulation of caveolin-1, a candidate tumor suppressor gene, in sarcomas. Am J Pathol. 2001;158: 833-839. (Pubitemid 32221776)
96. Toretsky JA, Kalebic T, Blakesley V, et al. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem. 1997;272: 30822-30827. (Pubitemid 27527522)
97. Rocchi A, Manara MC, Sciandra M, et al. CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis. J Clin Invest. 2010;120: 668-680.
98. Franzetti GA, Laud-Duval K, Bellanger D, et al. MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor. Oncogene. 2012;32: 3915-3921.
99. Sohn HW, Choi EY, Kim SH, et al. Engagement of CD99 induces apoptosis through a calcineurin-independent pathway in Ewing's sarcoma cells. Am J Pathol. 1998;153: 1937-1945. (Pubitemid 28550680)
100. Scotlandi K, Perdichizzi S, Bernard G, et al. Targeting CD99 in association with doxorubicin: an effective combined treatment for Ewing's sarcoma. Eur J Cancer. 2006; 42: 91-96. (Pubitemid 41814537)
101. Gellini M, Ascione A, Flego M, et al. Generation of human single-chain antibody to the CD99 cell surface determinant specifically recognizing Ewing's sarcoma tumor cells. Curr Pharm Biotechnol. 2012. [Epub ahead of print].
102. Mangerich A, Burkle A. How to kill tumor cells with inhibitors of poly(ADP-ribosyl)ation. Int J Cancer. 2011;128: 251-265.
103. Rouleau M, Patel A, Hendzel MJ, et al. PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 2010;10: 293-301.
104. He JX, Yang CH, Miao ZH. Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics. Acta Pharmacol Sin. 2010;31: 1172-1180.
105. Helleday T. Homologous recombination in cancer development, treatment and development of drug resistance. Carcinogenesis. 2010;31: 955-960.
106. O'Neil NJ, van Pel DM, Hieter P. Synthetic lethality and cancer: cohesin and PARP at the replication fork. Trends Genet. 2013;29: 290-297.
107. Solomon DA, Kim T, Diaz-Martinez LA, et al. Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science. 2011;333: 1039-1043.
108. Coleman RE, McCloskey EV. Bisphosphonates in oncology. Bone. 2011;49: 71-76.
109. Koto K, Murata H, Kimura S, et al. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents. Oncol Rep. 2010;24: 233-239.
110. Brown HK, Ottewell PD, Coleman RE, et al. The kinetochore protein Cenp-F is a potential novel target for zoledronic acid in breast cancer cells. J Cell Mol Med. 2011;15: 501-513.
111. Morii T, Ohtsuka K, Ohnishi H, et al. Inhibition of heatshock protein 27 expression eliminates drug resistance of osteosarcoma to zoledronic acid. Anticancer Res. 2010; 30: 3565-3571.
112. Mueller SK, Altvater B, Chen C, et al. Zoledronic acid negatively affects the expansion of in vitro activated human NK cells and their cytolytic interactions with Ewing sarcoma cells. Oncol Rep. 2013;29: 2348-2354.
113. Rabut G, Peter M. Function and regulation of protein neddylation. "Protein modifications: beyond the usual suspects" review series. EMBO Rep. 2008;9: 969-976.
114. Petroski MD, Deshaies RJ. Mechanism of lysine 48-linked ubiquitin-chain synthesis by the cullin-RING ubiquitin-ligase complex SCF-Cdc34. Cell. 2005;123: 1107-1120. (Pubitemid 41785424)
115. Soucy TA, Smith PG, Rolfe M. Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer. Clin Cancer Res. 2009;15: 3912-3916.
116. Paramore A, Frantz S. Bortezomib. Nat Rev Drug Discov. 2003;2: 611-612.
117. Milhollen MA, Narayanan U, Soucy TA, et al. Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover. Cancer Res. 2010;71: 3042-3051.
118. Luo Z, Yu G, Lee HW, et al. The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth. Cancer Res. 2012;72: 3360-3371.
119. Swords RT, Kelly KR, Smith PG, et al. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood. 2010;115: 3796-3800.
120. Jia L, Li H, Sun Y. Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression. Neoplasia. 2011;13: 561-569.
121. Wei D, Li H, Yu J, et al. Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor. Cancer Res. 2012;72: 282-293.
122. Smith MA, Maris JM, Gorlick R, et al. Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2012;59: 246-253.
123. Douglas D, Hsu JH, Hung L, et al. BMI-1 promotes ewing sarcoma tumorigenicity independent of CDKN2A repression. Cancer Res. 2008;68: 6507-6515.
124. Burdach S, Plehm S, Unland R, et al. Epigenetic maintenance of stemness and malignancy in peripheral neuroectodermal tumors by EZH2. Cell Cycle. 2009;8: 1991-1996.
125. Spivakov M, Fisher AG. Epigenetic signatures of stem-cell identity. Nat Rev Genet. 2007;8: 263-271. (Pubitemid 46439288)
126. Smith R, Owen LA, Trem DJ, et al. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer Cell. 2006;9: 405-416. (Pubitemid 43668735)
127. Fulda S, Kufer MU, Meyer E, et al. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene. 2001;20: 5865-5877. (Pubitemid 32937956)
128. Nakatani F, Tanaka K, Sakimura R, et al. Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein. J Biol Chem. 2003;278: 15105-15115. (Pubitemid 36799844)
129. Bracken AP, Helin K. Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat Rev Cancer. 2009;9: 773-784.
130. Enguita-German M, Gurrea M, Schiapparelli P, et al. KIT expression and methylation in medulloblastoma and PNET cell lines and tumors. J Neurooncol. 2011;103: 247-253.
131. Ramakrishnan R, Fujimura Y, Zou JP, et al. Role of proteinprotein interactions in the antiapoptotic function of EWS-Fli- 1. Oncogene. 2004;23: 7087-7094. (Pubitemid 39319170)
132. Ahmad M, Rees RC, Ali SA. Escape from immunotherapy: possible mechanisms that influence tumor regression/ progression. Cancer Immunol Immunother. 2004;53: 844-854. (Pubitemid 39312652)
133. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100: 57-70. (Pubitemid 30046295)
134. Jensen PE. Recent advances in antigen processing and presentation. Nat Immunol. 2007;8: 1041-1048. (Pubitemid 47423752)
135. Tsukahara T, Kawaguchi S, Torigoe T, et al. Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5. Cancer Sci. 2006;97: 1374-1380. (Pubitemid 44614990)
136. Vitale M, Pelusi G, Taroni B, et al. HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. Clin Cancer Res. 2005;11: 67-72. (Pubitemid 40075779)
137. Ahn YO, Weigel B, Verneris MR. Killing the killer: natural killer cells to treat Ewing's sarcoma. Clin Cancer Res. 2010;16: 3819-3821.
138. Cho D, Shook DR, Shimasaki N, et al. Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res. 2010;16: 3901-3909.
139. Perez-Martinez A, de Prada Vicente I, Fernandez L, et al. Natural killer cells can exert a graft-vs-tumor effect in haploidentical stem cell transplantation for pediatric solid tumors. Exp Hematol. 2012;40:882-891, e881.
140. Berghuis D, de Hooge AS, Santos SJ, et al. Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition. J Pathol. 2009;218: 222-231.
141. Berghuis D, Schilham MW, Santos SJ, et al. The CXCR4- CXCL12 axis in Ewing sarcoma: promotion of tumor growth rather than metastatic disease. Clin Sarcoma Res. 2012;2:24.
142. Berghuis D, Schilham MW, Vos HI, et al. Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis. Clin Sarcoma Res. 2012;2:8.
143. Lehner M, Gotz G, Proff J, et al. Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection. PLoS One. 2012;7:e31210.
144. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407: 249-257.
145. van der Schaft DW, Hillen F, Pauwels P, et al. Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res. 2005;65: 11520-11528. (Pubitemid 41821710)
146. Zhou Z, Reddy K, Guan H, et al. VEGF(165), but not VEGF(189), stimulates vasculogenesis and bone marrow cell migration into Ewing's sarcoma tumors in vivo. Mol Cancer Res. 2007;5: 1125-1132. (Pubitemid 350137108)
147. Reddy K, Cao Y, Zhou Z, et al. VEGF165 expression in the tumor microenvironment influences the differentiation of bone marrow-derived pericytes that contribute to the Ewing's sarcoma vasculature. Angiogenesis. 2008;11: 257-267.
148. Reddy K, Zhou Z, Jia SF, et al. Stromal cell-derived factor-1 stimulates vasculogenesis and enhances Ewing's sarcoma tumor growth in the absence of vascular endothelial growth factor. Int J Cancer. 2008;123: 831-837. (Pubitemid 352032409)
149. Reddy K, Zhou Z, Schadler K, et al. Bone marrow subsets differentiate into endothelial cells and pericytes contributing to Ewing's tumor vessels. Mol Cancer Res. 2008;6: 929-936.
150. Lee TH, Bolontrade MF, Worth LL, et al. Production of VEGF165 by Ewing's sarcoma cells induces vasculogenesis and the incorporation of CD34+ stem cells into the expanding tumor vasculature. Int J Cancer. 2006;119: 839-846. (Pubitemid 44051447)
151. Dalal S, Berry AM, Cullinane CJ, et al. Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family. Clin Cancer Res. 2005;11: 2364-2378. (Pubitemid 40490198)
152. DuBois SG, Marina N, Glade-Bender J. Angiogenesis and vascular targeting in Ewing sarcoma: a review of preclinical and clinical data. Cancer. 2010;116: 749-757.
153. Lin PP, Pandey MK, Jin F, et al. EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model. Cancer Res. 2008;68: 8968-8975.
154. Torchia EC, Boyd K, Rehg JE, et al. EWS/FLI-1 induces rapid onset of myeloid/erythroid leukemia in mice. Mol Cell Biol. 2007;27: 7918-7934. (Pubitemid 350086425)
155. Ordonez JL, Osuna D, Garcia-Dominguez DJ, et al. The clinical relevance of molecular genetics in soft tissue sarcomas. Adv Anat Pathol. 2010;17: 162-181.
156. Morton CL, Houghton PJ. Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc. 2007;2: 247-250. (Pubitemid 47040037)
157. Rubio-Viqueira B, Hidalgo M. Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients. Clin Pharmacol Ther. 2009;85: 217-221.
158. Gonzalez I, Vicent S, de Alava E, et al. EWS/FLI-1 oncoprotein subtypes impose different requirements for transformation and metastatic activity in a murine model. J Mol Med. 2007;85: 1015-1029. (Pubitemid 47282792)
159. Kelland LR, Sharp SY, Rogers PM, et al. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17- demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst. 1999;91: 1940-1949.
160. Thomas RK, Baker AC, Debiasi RM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007;39: 347-351. (Pubitemid 46328493)
161. Shukla N, Ameur N, Yilmaz I, et al. Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin Cancer Res. 2012;18: 748-757.
162. Ogita S, Lorusso P. Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs. Target Oncol. 2011;6: 103-117.
163. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006;439: 358-362. (Pubitemid 43128863)